The FDA is one of the most sweeping regulatory agencies in the United States by product scope. Its jurisdiction covers approximately 78 cents of every dollar spent by US consumers — food, drugs, biological products, medical devices, animal feed, veterinary drugs, cosmetics, tobacco products, and dietary supplements. Understanding who FDA regulates, how it enforces compliance, and what the current enforcement data shows is foundational knowledge for any employer or professional in a regulated industry.
What the FDA Regulates
Key Statistics
- In 2022, the FDA conducted approximately 15,443 inspections; in 2023, that number rose to 18,169 — a 17.6% increase.
- In fiscal year 2025, the FDA conducted 694 more inspections compared to fiscal year 2024.
- Between July 1 and December 3, 2025, the agency issued 327 warning letters, representing a 73% increase over the same period in 2024.
- In fiscal year 2025, the FDA issued 58 untitled letters — up dramatically from just five in 2024 and four in 2023.
- The food and cosmetics industries recorded a significant increase of 1,540 inspections from 2024 to 2025, while the device industry experienced an uptick in both warning letters and inspections.
How FDA Enforcement Works
FDA enforcement operates through a tiered system of escalating actions. Most compliance issues are resolved voluntarily. The agency reserves its most serious tools — injunctions, seizures, and criminal referrals — for situations where voluntary compliance has failed or where the violation poses an immediate public health risk.
The Three Inspection Classifications
The agency assigns inspected firms a final classification: No Action Indicated (NAI) indicates a facility is in an acceptable state of compliance and was usually not issued a Form 483 at the conclusion of the inspection. Voluntary Action Indicated (VAI) indicates the inspection found objectionable conditions or practices but the agency has determined the facility can voluntarily correct its deficiencies and will not recommend any action. Official Action Indicated (OAI) is the most serious classification and typically triggers a regulatory action such as a warning letter.
Facility is in acceptable compliance. No 483 issued or objectionable conditions addressed. No regulatory action recommended.
Objectionable conditions found but facility can voluntarily correct. No formal regulatory action recommended at this stage.
Significant violations found. Regulatory action recommended. Typically followed by a warning letter or other formal action.
The 2025 Enforcement Shift: AI, Unannounced Inspections, and Increased Volume
In June 2025, the FDA launched its internal AI system “Elsa,” introducing new analytical tools and possibilities in FDA’s arsenal. According to FDA, predictive analytics means inspections are increasingly risk-based rather than random, reducing the likelihood of surprise visits for low-risk facilities while intensifying scrutiny for those flagged by data anomalies.
In line with recent policy shifts, the FDA announced in a May 6, 2025, press release that it has expanded its use of unannounced inspections at foreign manufacturing facilities, particularly in countries such as China and India, which supply a sizable portion of active pharmaceutical ingredients for the U.S. market. This initiative aims to eliminate the double standard between domestic and foreign manufacturers and to expose noncompliance that might otherwise be concealed during preannounced inspections.
The Drug Industry: The Largest Enforcement Spike in 2025
The drug industry recorded 82 more warning letters compared to the prior year. This surge is largely attributable to a concentrated enforcement action on September 9, 2025, when the FDA launched a crackdown on deceptive drug advertising. On that day alone, the agency issued over 60 warning letters.
This single-day enforcement action is the largest coordinated warning letter issuance in FDA history and reflects the agency’s use of themed enforcement campaigns — targeting a specific compliance issue across many companies simultaneously — as an alternative to case-by-case enforcement.
In regulated industry compliance assessments, the most consistent gap between FDA’s enforcement priorities and facility preparedness is in documentation. Warning letters and 483 observations that result in OAI classifications are, in a large proportion of cases, not about the underlying quality failure — they are about the inadequacy of the facility’s response to prior observations. A facility that receives a 483, provides an inadequate corrective action response, and then receives a warning letter has typically had the opportunity to resolve the matter before escalation. The response to the 483 is the compliance moment that matters most.
What the Enforcement Data Means for Regulated Entities
The pattern across FY2025 is consistent: more inspections, more warning letters, more untitled letters, and a new AI-driven targeting system that deprioritizes low-risk facilities while escalating scrutiny on those that show data anomalies. The implications are practical.
For food and cosmetics companies, the 1,540 inspection increase is the most dramatic shift by volume. MoCRA (the Modernization of Cosmetics Regulation Act of 2022) is the driver for cosmetics — FDA now has registration, facility listing, and adverse event reporting requirements for cosmetics manufacturers that did not exist before 2022, and enforcement of these new requirements is beginning.
For pharmaceutical manufacturers, the AI targeting system means that facilities with prior 483 observations, unresolved corrective actions, or anomalous product quality data are more likely to be selected for inspection than those with clean compliance histories. The September 2025 coordinated advertising enforcement action signals that FDA will use bulk simultaneous enforcement as a tool when it identifies a systemic industry-wide compliance gap.
For medical device manufacturers, the increase in both warning letters and inspections continues a multi-year trend. The device industry has seen elevated enforcement activity since FDA’s work on the quality management system regulation (QSR) modernization, which aligned 21 CFR Part 820 more closely with ISO 13485.
Sources
- Reed Smith, “FDA Inspections in 2025: Heightened Rigor, Data-Driven Targeting” (December 2025)
- FDA, “Inspection Classification Database”
- FDA, “Inspection Observations”
- FDA Data Dashboard
- Foley and Lardner, “2024 CPSC and FDA Enforcement Trends”
- Ropes and Gray, “FDA Enforcement Review: Looking Back at 2025” (January 2026)
- FDA, “About FDA” — What We Regulate